Bionoid Pharma, Inc. Engages Olayinka Oyebola & Co. as PCAOB External Auditor for Annual Financial Audit
Bionoid Pharma (OTC PINK:BINP) has appointed Olayinka Oyebola & Co., a PCAOB-registered firm, as its external auditor. The firm will conduct independent audits of BINP's financial statements for fiscal years ending December 31, 2022, and 2023. The audit will examine bookkeeping practices, internal controls, and US GAAP compliance, aiming to provide stakeholders with a clear view of the company's financial position. Wayne Cockburn, Interim CEO, states this engagement reflects their commitment to establishing robust financial governance while pursuing strategic objectives in the health and wellness sector.
Bionoid Pharma (OTC PINK:BINP) ha nominato Olayinka Oyebola & Co., una società registrata presso la PCAOB, come suo revisore esterno. L'azienda condurrà audit indipendenti dei bilanci di BINP per gli anni fiscali che terminano il 31 dicembre 2022 e 2023. L'audit esaminerà le pratiche di contabilità, i controlli interni e la conformità ai principi contabili statunitensi (US GAAP), con l'obiettivo di fornire agli stakeholder una visione chiara della posizione finanziaria dell'azienda. Wayne Cockburn, CEO ad interim, afferma che questo incarico riflette il loro impegno per stabilire una solida governance finanziaria mentre perseguono obiettivi strategici nel settore della salute e del benessere.
Bionoid Pharma (OTC PINK:BINP) ha nombrado a Olayinka Oyebola & Co., una firma registrada en la PCAOB, como su auditor externo. La firma llevará a cabo auditorías independientes de los estados financieros de BINP para los años fiscales que terminan el 31 de diciembre de 2022 y 2023. La auditoría examinará las prácticas contables, los controles internos y el cumplimiento de los US GAAP, con el objetivo de proporcionar a los interesados una visión clara de la situación financiera de la empresa. Wayne Cockburn, CEO interino, indica que este compromiso refleja su dedicación a establecer una sólida gobernanza financiera mientras persiguen objetivos estratégicos en el sector de la salud y el bienestar.
Bionoid Pharma (OTC PINK:BINP)가 Olayinka Oyebola & Co., PCAOB에 등록된 외부 감사인으로 지명했습니다. 이 회사는 2022년 및 2023년 12월 31일 종료 회계 연도의 BINP 재무 제표에 대한 독립 감사 를 수행할 것입니다. 감사는 장부 관리 관행, 내부 통제 및 미국 GAAP 준수를 검토하여 이해 관계자에게 회사의 재무 상태에 대한 명확한 관점을 제공하는 것을 목표로 합니다. Wayne Cockburn 임시 CEO는 이번 계약이 건강 및 웰니스 분야에서 전략적 목표를 추구하면서 강력한 재무 거버넌스를 수립하려는 의지를 반영한다고 말했습니다.
Bionoid Pharma (OTC PINK:BINP) a nommé Olayinka Oyebola & Co., une société enregistrée auprès de la PCAOB, comme auditeur externe. La société effectuera des audits indépendants des états financiers de BINP pour les exercices fiscaux se terminant le 31 décembre 2022 et 2023. L'audit examinera les pratiques comptables, les contrôles internes et la conformité aux US GAAP, dans le but de fournir aux parties prenantes une vue claire de la situation financière de l'entreprise. Wayne Cockburn, PDG par intérim, déclare que cet engagement reflète leur volonté d'établir une solide gouvernance financière tout en poursuivant des objectifs stratégiques dans le secteur de la santé et du bien-être.
Bionoid Pharma (OTC PINK:BINP) hat Olayinka Oyebola & Co., eine bei der PCAOB registrierte Firma, als externen Prüfer ernannt. Die Firma wird unabhängige Prüfungen der Finanzberichte von BINP für die am 31. Dezember 2022 und 2023 endenden Geschäftsjahre durchführen. Die Prüfung wird Rechnungslegungspraktiken, interne Kontrollen und die Einhaltung der US GAAP untersuchen, mit dem Ziel, den Interessengruppen einen klaren Überblick über die finanzielle Lage des Unternehmens zu geben. Wayne Cockburn, interim CEO, erklärt, dass dieses Engagement ihr Bekenntnis zur Etablierung robuster finanzieller Governance widerspiegelt, während sie strategische Ziele im Gesundheits- und Wellnesssektor verfolgen.
- Engagement of PCAOB-registered auditor enhances financial transparency and regulatory compliance
- Implementation of comprehensive financial audit covering two fiscal years (2022-2023)
- Financial statements for 2022 and 2023 remain unaudited, indicating delayed financial reporting
- Current trading on OTC Pink market suggests lower tier listing status
TORONTO, ON and NEW YORK, NY / ACCESSWIRE / November 7, 2024 / Bionoid Pharma, Inc. ("BINP") (OTC PINK:BINP) is pleased to announce the formal engagement of Olayinka Oyebola & Co., a PCAOB-registered firm, as the company's external auditor. This appointment marks an important step in enhancing BINP's commitment to transparency, accountability, and adherence to regulatory standards in financial reporting.
Under this agreement, Olayinka Oyebola & Co. will conduct an independent audit of BINP's financial statements for the fiscal years ending December 31, 2022, and December 31, 2023. The audit will be performed in accordance with the Public Company Accounting Oversight Board (PCAOB) standards and will include a review of BINP's bookkeeping practices, internal controls, and compliance with US GAAP. This rigorous audit process aims to provide shareholders and stakeholders with a clear and accurate view of the company's financial health.
"The engagement of Olayinka Oyebola & Co. reflects our commitment to establishing robust financial governance as we pursue our long-term strategic objectives," said Wayne Cockburn, Interim CEO of Bionoid Pharma. "Their expertise in PCAOB-compliant audits will provide the confidence and assurance needed for our stakeholders and prospective investors as BINP continues to grow and execute its acquisition strategy in the health and wellness sector."
For further information, contact:
Wayne Cockburn, Interim CEO
Phone: (905) 505-0770
bionoidpharma@gmail.com
www.bionoidpharma.com
SOURCE: Bionoid Pharma, Inc.
View the original press release on accesswire.com
FAQ
What auditing firm did Bionoid Pharma (BINP) engage for its financial audit?
Which fiscal years will be audited for Bionoid Pharma (BINP)?
What is the current trading status of Bionoid Pharma (BINP)?
